Table of Contents

PROSPECTUS SUPPLEMENT NO. 4 DATED January 2, 2009 Filed Pursuant to Rule 424(b)(3)
(To Prospectus dated April 1, 2008) Registration No. 333-150027
 
$200,000,000
 
(OSI PHARMACEUTICALS LOGO)
 
3% Convertible Senior Subordinated Notes due 2038
and 4,470,273 Shares of Common Stock
Issuable Upon Conversion of the Notes
 
This prospectus supplement relates to resales by selling securityholders of our 3% Convertible Senior Subordinated Notes due 2038 and shares of our common stock issuable upon conversion of the notes.
 
This prospectus supplement must be read in conjunction with the Prospectus dated April 1, 2008 (the “Prospectus”).
 
SEE “RISK FACTORS” BEGINNING ON PAGE 7 OF THE PROSPECTUS, AS THEY MAY BE MODIFIED AND INCORPORATED BY REFERENCE, TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING THE NOTES OR OUR COMMON STOCK.
 
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
 
The date of this prospectus supplement is January 2, 2009


TABLE OF CONTENTS

SELLING SECURITYHOLDERS


Table of Contents

 
SELLING SECURITYHOLDERS
 
The information in the table appearing in the Prospectus under the heading “Selling Securityholders” is superseded by the information appearing in the following table based on information provided to us by the selling securityholders as of January 2, 2009:
 
                                         
    Principal
          Number of
          Number of
 
    Amount of Notes
    Number of
    Shares of
    Principal
    Shares of
 
    Beneficially
    Shares of
    Common Stock
    Amount of Notes
    Common Stock
 
    Owned Prior to
    Common Stock
    Issuable Upon
    Beneficially
    Beneficially
 
    the Offering and
    Beneficially
    Conversion of the
    Owned Upon
    Owned Upon
 
    That May
    Owned Prior to
    Notes That May
    Completion of
    Completion of
 
Selling Securityholder
  be Offered     the Offering(1)     be Offered(2)     the Offering(3)     the Offering(3)  
 
Absolute Strategies Fund(4)
  $ 392,000       8,762       8,762                  
Arkansas PERS(5)
  $ 500,000       11,176       11,176                  
Boilermakers Blacksmith Pension
Trust(5)
  $ 520,000       11,623       11,623                  
Citadel Equity Fund, Ltd.(6)(7)
  $ 64,750,000       1,514,301 (8)     1,447,247               67,054  
Continental Assurance Company on behalf of its Separate Account(E)(6)
  $ 100,000       2,235       2,235                  
CSV Limited(9)
  $ 1,000,000       22,351       22,351                  
DBAG London(6)(10)
  $ 31,200,000       697,361       697,361                  
FPL Group Employees Pension Plan(5)
  $ 275,000       6,147       6,147                  
Highbridge Convertible Arbitrage Master Fund, L.P.(11)
  $ 1,600,000       35,762       35,762                  
Highbridge International LLC(12)
  $ 8,650,000       388,751 (13)     193,339               195,412  
Jabcap Multi Strategy Master Fund Limited(14)
  $ 10,125,000       226,307       226,307                  
J-Invest Ltd(15)
  $ 2,375,000       53,084       53,084                  
Merrill Lynch, Pierce, Fenner & Smith Incorporated(6)
  $ 500,000       21,232 (16)     11,176               10,056  
SSI Hedged Convertible Opportunity Fund(4)
  $ 1,170,000       26,151       26,151                  
Tamalpais Global Partners Master Fund Ltd.(17)
  $ 2,155,000       148,130 (18)     48,167               99,963  
United Technologies Corporation Master Retirement Trust(4)
  $ 383,000       8,561       8,561                  
Viacom, Inc. Pension Plan
Master Trust(4)
  $ 55,000       1,229       1,229                  
Vicis Capital Master Fund(19)
  $ 6,000,000       134,108       134,108                  
Visium Balanced Fund, LP(20)
  $ 4,470,000       99,910       99,910                  
Visium Balanced Offshore Fund, Ltd.(20)
  $ 10,060,000       224,854       224,854                  
Wells Fargo & Company(6)
  $ 1,000,000       22,351       22,351                  
Xavex Convertible Arbitrage 5 (6)(21)
  $ 350,000       7,823       7,823                  
All other holders of notes or future transferees, pledges, donees, assignees or successors of any such
holders (22)(23)
  $ 52,370,000       1,170,538       1,170,538                  
 
 
(1) Shares in this column include the maximum number of shares of common stock issuable upon conversion of the notes and a maximum number of additional shares as described in footnotes (8), (13), (16) and (18) below.
 
(2) Assumes conversion of all of the securityholders’ notes at a conversion rate of approximately 22.3513 shares of common stock per $1,000 principal amount of the notes. This conversion rate is subject to adjustment, however, as described under “Description of the Notes — Conversion Rights.” As a result, the number of shares of common stock issuable upon conversion of the notes may increase or decrease in the future.


2


Table of Contents

 
(3) Assumes that each selling securityholder will sell all of the notes and common stock issuable upon conversion of the notes owned by the selling securityholder and covered by this Prospectus and will retain all other securities of the Company held by it other than those covered by this Prospectus.
 
(4) John Gottfurcht, Amy Jo Gottfurcht and George Douglas are the shareholders of SSI Investment Management, which has ultimate voting and dispositive power over the securities stated as beneficially owned by this selling securityholder. Messrs. Gottfurcht and Douglas and Ms. Gottfurcht disclaim beneficial ownership of the securities stated as beneficially owned by this selling securityholder.
 
(5) Ann Houlihan may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.
 
(6) This selling securityholder is, or is an affiliate of, a registered broker-dealer. Each selling securityholder that is a registered broker-dealer or affiliated with a registered broker-dealer has represented to us that the notes and shares of common stock issuable upon conversion of the notes held by it were purchased in the ordinary course of business and that at the time of purchase, it did not have any agreements or understandings, directly or indirectly, with any person to distribute the notes held by it or the shares of common stock issuable upon conversion of the notes held by it. To the extent that we become aware that such entities did not acquire their notes or underlying common stock in the ordinary course of business, or did have such an agreement or understanding, we will file a supplement to the Prospectus to designate such affiliate as an “underwriter” within the meaning of the Securities Act.
 
(7) Citadel Limited Partnership, or CLP, is the trading manager of Citadel Equity Fund Ltd., or CEF, and consequently has investment discretion over securities held by CEF. Citadel Investment Group, L.L.C., or CIG, controls CLP. Kenneth C. Griffin controls CIG and therefore has ultimate investment discretion over securities held by CEF. CLP, CIG and Mr. Griffin each disclaim beneficial ownership of the securities held by CEF. Goldman Sachs, Credit Suisse and Deutsche Bank Securities are the beneficial owners of $23,250,000, $11,800,000 and $29,700,000 principal amount of notes, respectively.
 
(8) Includes a maximum of 67,054 shares of common stock issuable upon conversion of $3,000,000 principal amount of registered notes beneficially owned by this selling securityholder.
 
(9) Eric White may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.
 
(10) John Arnone may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.
 
(11) Highbridge Capital Management, LLC is the trading manager of Highbridge Convertible Arbitrage Master Fund, L.P. and has voting control and investment discretion over the securities held by Highbridge Convertible Arbitrage Master Fund, L.P. Glenn Dubin and Henry Swieca control Highbridge Capital Management, LLC and have voting control and investment discretion over the securities held by Highbridge Convertible Arbitrage Master Fund, L.P. Each of Highbridge Capital Management, LLC, Glenn Dubin and Henry Swieca disclaims beneficial ownership of the securities held by Highbridge Convertible Arbitrage Master Fund, L.P.
 
(12) Highbridge Capital Management, LLC is the trading manager of Highbridge International LLC and has voting control and investment discretion over the securities held by Highbridge International LLC. Glenn Dubin and Henry Swieca control Highbridge Capital Management, LLC and have voting control and investment discretion over the securities held by Highbridge International LLC. Each of Highbridge Capital Management, LLC, Glenn Dubin and Henry Swieca disclaims beneficial ownership of the securities held by Highbridge International LLC.
 
(13) Includes a maximum of 195,412 shares of common stock issuable upon conversion of $5,750,000 principal amount of 2025 Notes beneficially owned by this selling securityholder.
 
(14) Jabre Capital Partners SA is the investment manager of Jabcap Multi Strategy Master Fund Limited. Philippe Jabre is the sole owner of Jabre Capital Partners SA and may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.
 
(15) Jabre Capital Partners SA is the investment manager of J-Invest Ltd. Philippe Jabre is the sole owner of Jabre Capital Partners SA and may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.


3


Table of Contents

 
(16) Includes a maximum of 10,056 shares of common stock issuable upon conversion of $503,000 principal amount of 2023 Notes beneficially owned by this selling securityholder.
 
(17) Paul Giordano may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.
 
(18) Includes a maximum of 99,963 shares of common stock issuable upon conversion of $5,000,000 principal amount of 2023 Notes beneficially owned by this selling securityholder.
 
(19) Vicis Capital LLC is the investment manager of this selling securityholder. Shad Stastney, John Succo and Sky Lucas control Vicis Capital LLC and therefore may be deemed to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder. Each of Shad Stastney, John Succo and Sky Lucas disclaim beneficial ownership of any of the securities offered by this selling securityholder.
 
(20) Visium Asset Management, LLC, or VAM, is the investment adviser to the selling securityholder. Mark Gottlieb is a member of VAM and as Chief Compliance Officer has been granted authority to exercise voting power or investment control over the securities stated as beneficially owned by this selling securityholder.
 
(21) Ramius Capital is the investment adviser of Xavex Convertible Arbitrage 5, or Xavex, and consequently has voting control and investment discretion over securities held by Xavex. Ramius Capital disclaims beneficial ownership of the shares held by Xavex. Peter A. Cohen, Morgan B. Stark, Thomas W. Strauss and Jeffrey M. Solomon are the sole managing members of C4S & Co., L.L.C., the sole managing member of Ramius Capital. As a result, Messrs. Cohen, Stark, Strauss and Solomon may be considered beneficial owners of any shares deemed to be beneficially owned by Ramius Capital. Messrs. Cohen, Stark, Strauss and Solomon disclaim beneficial ownership of these shares.
 
(22) Information about other selling securityholders will be set forth in prospectus supplements or amendments, if required.
 
(23) Assumes that any other holders of the notes or any future pledges, donees, assignees, transferees or successors of or from any other such holders of the notes do not beneficially own any shares of common stock other than the common stock issuable upon conversion of the notes at a conversion rate of approximately 22.3513 shares of common stock per $1,000 principal amount of the notes.


4

Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Osi Pharmaceuticals Charts.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Osi Pharmaceuticals Charts.